A lthough supporting research on aging was a laudable goal in the 1970s, it is an imperative now. The growth of the older population of the United States is impressive; from approximately 46 million persons in 2014, it is likely that the population aged 65 and older will almost double by mid-century, and the population aged 85 and older is increasing at an even faster rate. 1 Although a decrease in the prevalence of disability in the last decades of the previous century has accompanied the increase in life expectancy at older ages, there are signs that the favorable trend in disability at older ages has stopped and has even begun to reverse in recent years, especially for U.S. women. 2 In anticipation of the accelerated aging of the U.S. population, the National Institute on Aging (NIA), one of 27 institutes and centers (ICs) at the National Institutes of Health (NIH), was founded in 1974 to conduct and support research on aging and the health and well-being of older people. NIA plays a significant role in leading or supporting research on aging, and its interests span the fundamental processes that contribute to aging and their impact on systems; diseases and conditions for which aging is a risk factor; and interventions that may prevent, delay, or treat these conditions or otherwise contribute to an extension of healthy, active years of life.
Collaborations have been critical to the successful advancement of biomedical science and, in the context of four decades of NIA-funded aging research, to understanding the issues that affect health and function at older ages. NIH and NIA promote and model collaborative science and have fostered a wide range of transagency programs and initiatives, as well as significant public-private partnerships, in the recent past-examples of which are discussed below. The level of visibility that aging research has attained in today's environment has enhanced these collaborations, and the products of these research collaborations, when individuals, clinicians, and policymakers use them to foster improvements in practice, should yield tangible additional benefits across all sectors of our culture, including the workforce, transportation, housing, and perhaps most critically-healthcare.
NIA's investment in its research portfolio has approximately doubled in the past 11 years, from a budget of just over $1 billion in fiscal year (FY) 2006 to just over $2 billion in FY2017. What has this funding made possible? NIA is the lead institute at NIH for Alzheimer's disease (AD) and related dementias (ADRD) research, and we have made tremendous strides in this area of investigation -from the discovery of additional risk genes for AD, the development of interventions that can help caregivers experience less stress, and advances in imaging that enable testing of very early interventions in individuals at high risk for AD, to the crafting of a complex research infrastructure. In collaboration with NIH overall, these actions will enable us to accelerate current and future exploration of new clinical targets. Many of these advances have occurred as the result of collaborations across NIH and beyond. As NIA moves forward, collaborations to leverage the research investments by the institute will become even more critical as the science becomes more complex, and resources required to answer complex questions are best leveraged in cooperation with other scientific groups.
In a previous commentary in the Journal of the American Geriatrics Society, NIA authors discussed the growth of NIA's research portfolio and of several of its flagship programs, such as the Baltimore Longitudinal Study on Aging and the Interventions Testing Program. 3 In this article, we revisit one of these programs-the Health and Retirement Study (HRS)-and explore three other NIA priorities: geroscience research, falls injury prevention in elderly adults, and implementation of the National Plan to Address Alzheimer's Disease. A key feature of each of these activities is collaboration-across the NIH, the federal government, and nongovernmental organizations.
GEROSCIENCE RESEARCH
The concept of "geroscience" was developed at NIH through NIA leadership to merge interests of basic aging and disease-focused researchers. It is inherently a field of collaborative work. Although the public's interest in a "fountain of youth" may grow as its average age increases, NIA is not satisfied with increasing lifespan if this involves more years encumbered by myriad health conditions that lead to disability and diminish quality of life. A primary goal of NIA is increasing "healthspan," which focuses on extending a person's healthy and productive years. Many in the research community-as well as at NIA-believe that slowing the rate of aging may have a central effect on the age of onset and the severity of these deleterious conditions. Geroscience is an emerging interdisciplinary scientific field that aims to understand the relationship between aging and agerelated diseases and dysfunctions and how these intersect with frailty and resilience. Researchers in the field hypothesize that slowing the rate of aging will improve the health of older adults by delaying the onset or reducing the severity of most chronic diseases and frailty-improving healthspan.
NIA has led the expansion of the geroscience field by launching several collaborations. In 2012, NIA launched a GeroScience Interest Group 4 to bring together NIH ICs with an interest in research on the mechanisms noted above for their potential broad effect on the onset and progression of diseases of aging. Twenty-one of the 27 NIH ICs participate in this interest group, providing intellectual and financial capital to address the highest-priority problems in the field. Recently, research has been funded in response to two funding opportunity announcements emanating from the GeroScience Interest Group that demonstrate collaborative efforts among NIH institutes (Table 1) .
NIA also has led the development of two large summit meetings focused on geroscience in collaboration with several nongovernmental entities. In the fall of 2013, NIH held (in collaboration with the Alliance for Aging Research and the Gerontological Society of America (GSA)), the first-ever geroscience summit, entitled "Advances in Geroscience: Impact on Healthspan and Chronic Disease." The goals of this initial conference were to generate a new vision of collaborative interactions that will advance understanding of how the molecular, cellular, and systemic processes of aging affect the etiology of chronic diseases; to identify strategic scientific areas of overlap of different chronic diseases; and to suggest new research interactions or directions to address areas that will promote health. Two publications on the importance and overarching effect of geroscience emerged from this meeting. 5, 6 Based on the overwhelmingly positive response to the first summit, in the spring of 2016, NIH supported (in collaboration with the New York Academy of Sciences, the American Federation for Aging Research, and the GSA) a second meeting entitled "Disease Drivers of Aging: 2016 Advances in Geroscience." The goal of this second summit was to explore "reverse geroscience": the effect of chronic diseases and their treatment on the rate of aging. Like the first summit, the meeting brought together a wide spectrum of researchers-representatives from pharmaceutical companies, government agencies, and nonprofit organizations-who work in the fields of aging-related diseases (human immunodeficiency virus, acquire immunodeficiency syndrome, cancer, diabetes mellitus) and in aging research to understand the effect of these conditions on aging. Both summits resulted in meeting publications that have expanded conversations about this emerging field of research (see discussion above and additional references 7, 8 ). In addition, recognizing the potential importance of this sort of research to clinical care and disease management, the American Geriatrics Society and the GSA, two of the major organizations involved in aging and geriatrics in the United States, have recently developed formal Geroscience Interest Groups.
STRATEGIES TO REDUCE INJURIES AND DEVELOP CONFIDENCE IN ELDERLY ADULTS
Geriatricians and other healthcare providers appreciate that one of the greatest risks to older adults is that of falling and recognize that a team effort is needed to prevent falls. 9 Nearly 30% of adults aged 65 and older fall each year, and falls are the leading cause of injuries (including fatal injuries) in this age group. 10 The causes of this greater risk are multifactorial and include limitations in mobility and balance and susceptibility to environmental hazards. NIA-funded research has supported the testing of multiple strategies that can reduce these risks, [11] [12] [13] [14] [15] [16] [17] [18] but how can the most successful of these findings be applied to a geographically and ethnically diverse community of older adults?
To address this critically important public health challenge, NIA developed a falls injuries prevention partner ship with the Patient-Centered Outcomes Research Institute in 2013. The product of this partnership thus far was the release of a request for applications for a randomized clinical trial of multifactorial, evidence-based, personcentered strategy for preventing serious fall-related injuries in noninstitutionalized older people. NIA awarded funding for the Strategies To Reduce Injuries and Develop Confide nce in Elders (STRIDE) trial-managed by investigators at Harvard, Yale, and the University of California at Los Angeles-in 2014. The focus of STRIDE has been to test a customized prevention strategy and concept of a fall care manager in various healthcare systems and communities to reduce serious fall-related injuries in individuals aged 75 and older. Individual prevention strategies will be based on personal assessments for fall risks, and control participants will receive current standard of care treatment. This study is unique in its level of stakeholder engagement, one of the goals of the Patient-Centered Outcomes Research Institute collaboration. In addition to the universities listed above, investigators from NIA-funded Claude D. Pepper Older Americans Independence Centers, practitioners from 10 healthcare delivery systems and 86 primary care practice sites, and participant representatives are participating in the trial, which is expected to be completed in 2019. The participant representatives have been critical in bringing their own perspectives to the trial, in terms of topics such as intervention adherence and their hopes regarding outcomes.
THE HEALTH AND RETIREMENT STUDY
The HRS is a prime example of a research infrastructure that NIA supports that facilitates a broad range of collaborations. Much of what researchers and policymakers understand about the positive and negative changes that affect people through their retirement years has emerged from this longstanding NIA-supported project (http://hrson line.isr.umich.edu/). Now almost three decades old, the HRS is a longitudinal study of a sample of more than 20,000 individuals and their partners, representative of the U.S. population aged 50 and older, and funded by the NIA and the Social Security Administration (SSA). The study was initiated in 1992, and data on health, cognitive status, use of health services, early-life history, psychological traits and well-being, family structure, labor force participation, and economic status have been collected every 2 years, with other measures collected every 4 years, including measures of physical performance and healthrelated biomarkers. Every 6 years, the HRS enrolls a new birth cohort to maintain its representativeness of older U.S. households; households with low incomes and low educational attainment are proportionately sampled, and African-American and Hispanic households are oversampled. Participants are followed from enrollment when they were aged 50 to 56 through the life course until death. Collaborations with the Centers for Medicare and Medicaid Services (CMS; healthcare costs and diagnoses), the National Center for Health Statistics (National Death Index), Department of Veterans Affairs (VA; health care records for HRS respondents who used services in the VA healthcare system), and the SSA (earnings records) have bolstered this study.
This collaborative approach to data collection has yielded some significant clinical findings-an association between severe sepsis and substantial and persistent new cognitive and functional disability in survivors 19 and a high rate of subsequent mortality that health status before sepsis does not explain 20 ; the utility of clinically accessible criteria for identifying persons with serious illness who could benefit from additional services 21 ; the critical need for older adults to prepare for the management of their medication and finances in later years 22 ; and an association between functional impairment and greater risk of 30-day all-cause hospital readmission in older Medicare beneficiaries, especially those admitted for heart failure, myocardial infarction, or pneumonia. 23 The HRS is not only a source of data regarding physical conditions of elderly adults, but also a source of information on cognitive status. The Harmonized Cognitive Assessment Protocol, an assessment conducted in 2016/17, and the Aging, Demographics, and Memory ancillary HRS study conducted in 2002/03 have provided unique insights into the national prevalence and trends of dementia, cognitive impairment without dementia, and the burdens of dementia caregiving. Examples of advances that have emerged from the Aging, Demographics, and Memory Study data include an estimation of the total cost of dementia in 2010 of between $161 billion and $221 billion 24 (comparable with that of heart disease and cancer) and more-recent estimates of a decline in dementia prevalence between 2000 and 2012, possibly due at least in part to an increase in educational attainment. 25 This resource, which would not be feasible without the collaborations with CMS, SSA, and VA, also provides genome-wide genotyping from more than 19,000 HRS respondents from the database of Genotypes and Phenotypes (dbGAP). This is a ready resource for researchers to use in ongoing and future investigations.
THE NATIONAL PLAN TO ADDRESS ALZHEIMER'S DISEASE
Work to advance understanding and potential treatment of AD/ADRD is a powerful example of leverage of collaborations to advance the science. Research on AD/ADRD has entered an era of unprecedented excitement and scientific opportunity with the signing of the National Alzheimer's Pro ject Act by President Obama in January 2011, which launched a series of events, including the establishment of a National Advisory Council for Alzheimer's Research, Care, and Services later that same year and the development of a National Plan to Address Alzheimer's Disease in 2012. Because the areas of focus of the National Plan go well beyond biomedical research, the Advisory Council includes membership from multiple federal agencies (Table 2) , as well as other public and private sector organizations.
Concomitant with this increased federal attention to the spectrum of needs resulting from these devastating conditions, increased funding was also made available, including additional NIH allocations in FY2012 and FY2013 and enhanced Congressional appropriations in FY2014 to FY2017. Over this period, NIA and NIH received an $875 million increase in AD/ADRD funding, with much of that increase occurring in the FY2016 ($350 million) and FY2017 ($400 million) appropriations.
The increase in AD/ADRD funding in the last several years has supported enhanced collaboration between NIA and multiple institutes across NIH-particularly the National Institute of Neurological Disorders and Stroke (NINDS), National Human Genome Research Institute (e.g., the Alzheimer's Disease Sequencing Project), and National Institute of Child Health and Human Development (e.g., the Down Syndrome Consortium, along with several other NIH ICs). To manage these increases in funds and to ensure that the AD/ADRD research community is poised to take advantage of any future funds provided, NIA and NINDS issued a number of targeted funding opportunity announcements from 2015 through 2017 to encourage proposals on a broad range of topics, including basic biology, translational research and clinical trials, health disparities, and the challenges of caregiving (http://www.nia.nih.gov/AD-FOAs). The topics in these funding opportunity announcements span all of NIA's research divisions-the Division of Geriatrics and Clinical Gerontology, Division of Behavioral and Social Research, Division of Aging Biology, Division of Neuroscience-and researchers from many subdisciplines of geriatrics will be needed to solve the problems outlined in the announcements. The response from the research community has been impressive, although innovative ideas from all corners of the aging research community are still needed to keep driving these fields ahead.
With respect to internal and external collaborations, the field of AD/ADRD research has been progressive. Twentytwo ICs already engage in AD/ADRD research (as of FY2016), and impressive examples of external partnerships are in place and are marked by unprecedented openness and data sharing. The Accelerating Medicines Partnership and the Alzheimer's Disease Neuroimaging Initiative are leading examples of successful public-private partnerships that have and continue to accelerate research in Alzheimer's.
AGING RESEARCH ACROSS NIH
These highlights showcase some key examples of NIA's investments in and collaborations on aging research, although as the profile of this research area has grown, so has interest among other ICs at the NIH. As of FY2016, the last year for which we have complete information, 24 NIH ICs and the NIH Office of the Director are investing in aging research at a level of just over $3 billion. This research spans a wide array of research areas, including the basic science of aging organ systems; aging-related diseases and conditions such as cancer, glaucoma, and hearing loss; the effect of aging on management of other health conditions, such as the human immunodeficiency virus; and research on intervening to improve these conditions and support caregivers helping loved ones who are experiencing them.
CONCLUSIONS
NIH has come a long way in supporting basic, translational, and clinical research on aging since 1974. As a result, we have greater insights into aging and are making significant and clinically meaningful strides in addressing the many conditions that contribute to morbidity and premature mortality in older people, although much more remains to be learned about the biology of these conditions and which interventions may be the most effective. We must have engagement and collaboration across scientific disciplines to make this happen, and we encourage readers of the Journal of the American Geriatrics Society to join us in this effort. also thank Dr. George Kuchel for his helpful advice as the manuscript was being conceived.
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